Navigation Links
Biomedical research center opens in Liverpool
Date:2/10/2009

Scientists at the University of Liverpool will launch a new national research centre to further understanding into infections such as HIV and tuberculosis.

The Centre, which will be opened by Sir William Stewart, Chairman of the Health Protection Agency, is one of 12 in the country to be funded by the National institute for Health Research (NIHR) as part of the Government's health research strategy. The joint venture has received 13.5 million funding from NIHR and a further 6.4million from the North West Development Agency. It will be run jointly by the University, the Royal Liverpool and Broadgreen University Hospitals Trust and the Liverpool School of Tropical Medicine.

The Centre will focus on four areas hospital and community acquired infections, chest infections, sexual health, and safety of antimicrobial drugs. Researchers will also have access to state-of-the-art facilities such as a new clinical research unit to trial new drug treatments and a medical microbiology facility for the identification and safe handling of bacteria.

Sir William said: "This is important work that will take place in first-rate facilities. I believe this Centre will be a magnet for our very best scientists, retaining and attracting the best brains to Liverpool and the North West, not just from elsewhere in the UK, but internationally. It is a privilege and pleasure to open such an important and worthwhile development."

Professor Peter Winstanley, Executive Director of the Biomedical Research Centre (BRC), said: "This prestigious new centre puts Liverpool at the cutting edge of research and means we can pioneer new drugs and diagnostic tools for a range of conditions. We will be investigating ways of alleviating suffering and treating infections which affect millions of people around the world."

The Centre will deliver 13 projects over the next five years, which include areas such as genetic testing to identify who is most likely to be allergic to penicillin, and vaccine development for pneumonia a major cause of death in children and adults worldwide. Research will also include identification of the factors that cause HIV patients to develop resistance to drug therapies.

Tony Bell, Royal Liverpool and Broadgreen University Hospitals Trust Chief Executive, said: "There has been groundbreaking medical research going on in Liverpool for many years.

The new Biomedical Research Centre acknowledges the excellence of that work and gives us the opportunity to make a much bigger impact on the treatment of infections worldwide. I am delighted to be part of such a vital development."

The opening of the Biomedical Research Centre will take place on Tuesday, 10 February at 11.00am in the Education Centre at the Royal Liverpool and Broadgreen University Hospital Trust.


'/>"/>

Contact: Samantha Martin
samantha.martin@liv.ac.uk
01-517-942-248
University of Liverpool
Source:Eurekalert

Related medicine news :

1. Dr. Huda Zoghbi to receive 2009 Vilcek Prize in biomedical research
2. Environmental Tectonics Corporations BioMedical Division Announces Additional Sales of Hyperbaric Monoplace Chambers
3. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
4. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
5. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
6. Response Biomedical Corporation Announces Change of Executives
7. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
8. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
9. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
10. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
11. Environmental Tectonics Corporations BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... , ... "Photo Cloud allows FCPX users to add favorited photos to any ... said Christina Austin - CEO of Pixel Film Studios. , To begin, select ... Presets include scenes with one, three, four or five focus points. There are five ...
(Date:1/21/2017)... ... ... Caronlab Australia, an Australian company known for health and beauty products such ... where it benefited from outstanding meetings with major retail buyers. , Caron Labs has ... this trade show, the company had the chance to demonstrate its products and provide ...
(Date:1/21/2017)... ... ... perfect set of tools for video editors that want to create the illusion of rack ... of Pixel Film Studios. , Video editors using ProDOF can add realistic depth of ... from one area into the next. ProDOF comes with 0.5 second, 1.0 second, 1.5 ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to ... the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of ... Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... announce that Redwood Family Dermatology has recently joined their multi-specialty medical ... a full range of cosmetic services. , “We’re excited to add this excellent ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... The American Pharmacists Association (APhA) is excited ... Medically Underserved Areas Enhancement Act (H.R. 592) ... was previously introduced in the 114 th session ... through pharmacists and their patient care services. ... (R-KY), G.K. Butterfield (D-NC), Tom ...
(Date:1/23/2017)... ALBANY, New York , January 23, 2017 ... Non-Invasive Prenatal Testing Market was valued at US$0.53 bn ... by expanding at a strong 17.50% CAGR between 2014 and 2022. ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... ...
(Date:1/23/2017)... PALMA, Spain , January 23, ... a clinical-stage biopharmaceutical company focused on treatments for ... has been enrolled in the Phase IIb "CaLIPSO ... the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease ... ESRD patients, in the last stage of chronic ...
Breaking Medicine Technology: